Evaluation of safety and efficacy of PDxane® in comparison to Clexane® in prophylaxis of venous thromboembolism in Major Gynecology Surgeries
Phase 3
- Conditions
- Venous Thromboembolism fallowing major gynecology surgery.Embolism and thrombosis of unspecified artery
- Registration Number
- IRCT20090914002459N2
- Lead Sponsor
- Pooyesh Darou Pharmaceuticals Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 200
Inclusion Criteria
Major Gynecology Surgeries
Adult (aged 18 and more)
Exclusion Criteria
Having clinical symptoms of Venus thrombosis
Having active bleeding or a high risk of bleeding
History of thromboembolic diseases
Malignancy
Pregnancy
Severe renal impairment
Significant liver disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevention of Venous Thromboembolism. Timepoint: 10 days after surgery. Method of measurement: History taking and clinical assessments.
- Secondary Outcome Measures
Name Time Method